Overview

A Phase I, Single-Center Study of PDC-APB in Healthy Volunteers

Status:
Completed
Trial end date:
2018-01-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled, single ascending dose study to assess the safety and tolerability of PDC-APB by intramuscular (IM) injection compared to placebo.
Phase:
Phase 1
Details
Lead Sponsor:
Hapten Sciences, Inc.